For our next #Employee Spotlight, we’re featuring Li Wang! Li is a Principal Investigator at Ventus. Today, she shares with us why science is her passion. #VentusTx
Ventus Therapeutics
Biotechnology Research
Waltham, Massachusetts 12,978 followers
Pioneering a unique approach to structure-based drug discovery. Located in Waltham, MA and Montreal, QC.
Über uns
At Ventus, we are pioneering a unique approach to structure-based drug discovery to address biologically validated, but difficult-to-drug targets. Others are building towards a future transformation of the drug development process … for Ventus, that future is already here. Our ReSOLVE™ platform integrates cutting-edge, structurally enabled, computational tools to identify and perfect new drug molecules for targets which have never been drugged or for which existing chemical matter leaves significant room for improvement. We are differentiated by our unique methods for modelling the properties of protein and water in motion. Optimal execution of these methods requires embedding our ReSOLVE platform with our world-class structural biology and chemistry teams. As our pipeline demonstrates, the ReSOLVE platform can find previously unknown pockets, better characterize known pockets, and solve the limitations of virtual screening, accelerating medicinal chemistry and structure-activity relationship (SAR) optimization. We are advancing a pipeline of new medicines to treat autoimmune and inflammatory diseases, neurological disorders, and cancer, and also generating a library of chemical matter for elusive targets for future pipeline needs and business development. Our team includes experienced biopharmaceutical executives, scientists who have delivered multiple approved medicines, and luminary academics spanning the fields of structural biology, immunology, and computational chemistry.
- Website
-
http://www.ventustx.com
External link for Ventus Therapeutics
- Industrie
- Biotechnology Research
- Größe des Unternehmens
- 11-50 Mitarbeiter
- Hauptsitz
- Waltham, Massachusetts
- Typ
- In Privatbesitz
- Gegründet
- 2019
Standorte
-
Primäre
100 Beaver St, Suite 202
Waltham, Massachusetts 02453, US
-
7150 Frederick-Banting
Montreal, Quebec H9S2A1, CA
Employees at Ventus Therapeutics
-
Jerel Davis
Managing Director at Versant Ventures
-
Amandine Chefson
Associate Director DMPK, at Ventus Therapeutics
-
Sammy Kim
Principal Scientist at Ventus Therapeutics
-
Dolca Thomas, MD
Biotech Executive; Board Member; R&D Leader; Physician Scientist; Coach/Mentor to Women and POC
Aktualisierungen
-
Ventus Therapeutics reposted this
For biotech startup Ventus Therapeutics, competing against Big Pharma can feel like David vs. Goliath. “How did David win the battle?” asks CEO Marcelo Bigal. “By being quick, by being fast, and by acting first. Basically that's it. Big Pharma has technologies, platforms, money, and critical mass. But they are slow.” Ventus is anything but slow: In just five years the company built a breakthrough platform for drug discovery, one that’s already yielded three clinical-stage therapies. In our latest Q&A, Bigal talks about competing with larger, better-resourced companies, putting patients first, and why having a shared mission is critical to success. https://lnkd.in/g_b6uYMq #biotech #medicine #innovation
-
-
We had such a wonderful time celebrating the grand opening of our new site in Montreal last week! This marked a special moment as we fondly remembered where #Ventus Therapeutics started just 5 years ago in Montreal and got to celebrate the growth and success that led to our move into our beautiful new home. The event was made even more special with the presence of our dedicated Ventus employees, their families, our supportive investors, esteemed board members, and our friends from the Montreal biotech community. Thank you to everyone who joined us. We look forward to all of the collaboration that will come in this space and working together toward discovering and designing novel #smallmoleculetherapeutics using our ML-enabled computational chemistry platform, ReSOLVE™. Read more: https://lnkd.in/eK6bHEA7
-
-
-
-
-
+2
-
-
Ventus Therapeutics reposted this
Finding cures for diseases like Parkinson’s means leaving no stone unturned. On the verge of developing a new kind of molecule to help combat the neurodegenerative condition, Ventus Therapeutics screened a documentary film about Parkinson’s for the entire company. The next day they invited a specialist to speak to everyone. On the third day, a patient with a severe form of Parkinson's shared his experience living with the disease. All three events were mandatory for employees, whether they were an accountant or a chemist. What was the impact? “Try telling someone at the company today that we’re giving up on Parkinson’s,” says CEO Marcelo Bigal. “They’re going to fight for it. The accountant is going to find money for Parkinson’s. This is our disease. Those events touched everyone at the company. They changed us.” Read our full Q&A with Bigal that spotlights how Ventus’s approach to drug discovery is unquestionably people-centered. https://lnkd.in/gveCgDTF #biotech #medicine #innovation
-
-
“ …we know exactly who we serve. We don't serve the target, we don't serve the protein, we don't serve the platform. We serve the patients who are struggling with a disease,” said Ventus CEO, Marcelo Bigal, M.D., Ph.D. in a recent interview with SoftBank Group Corp.’s Sōzō Insights Program. Marcelo talks about our people-centric operations in an open Q&A, diving deeper into his leadership style that’s driven our pipeline and company success for the past five years. Read more: https://lnkd.in/eSySgaVg
-
For our next #Employee Spotlight, we’re featuring Loraine Warner! Loraine is the Head of Clinical Operations at Ventus. Today, she shares with us what inspired her to pursue science! #VentusTx
-
-
Ventus’ Head of Platform Technologies, Jason Burch, appeared on Bloomberg Intelligence’s Tech Disruptors podcast to discuss our unique approach to discovering and designing novel small molecule therapeutics with our ReSOLVE drug discovery platform. Together with SoftBank Investment Advisers Investment Advisors’ John Cassidy, the two cover opportunities in health tech, #AI, platform technologies, and more pressing issues in #lifesciences and #healthcare with hosts Sam Fazeli and Mandeep Singh, CFA. Listen now: https://lnkd.in/ed4a5CkS
-
-
Ventus’ Chief Scientific Officer Michael Crackower, Ph.D., will take the panel stage tomorrow afternoon at Northeastern University College of Science’s Barnett Institute 50th Anniversary and Karger Medal Celebration. Led by Laurent Audoly, Ph.D., Senior Advisor to the Institute for Experiential AI at Northeastern, the panel will cover all things #drugdiscovery and #AI, exploring the latest advancements in the AI field and its potential use in healthcare.
-
We just announced that our partner, Novo Nordisk, has successfully dosed the first participant in a Phase 1 clinical study for NNC6022-0001, an oral NLRP3 inhibitor, making it the third Ventus-discovered compound to enter the clinic in the last nine months. Congratulations to Novo Nordisk on reaching this important clinical milestone. https://lnkd.in/euKVBUnZ